BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem

The hidden cost of getting treatment decisions wrong Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide, ranking among the ...

April 02, 2026 | Expert Insight | By Dr. Torbjørn Furuseth, CEO and Co-Founder, DoMore Diagnostics

Thermo Fisher Scientific Launches Gibco CHOvantage GS Cell Line Development Kit To Accelerate Biologics Development

Gibco CHOvantage GS Cell Line Development Kit delivers high productivity, streamlined timelines and royalty-free, clinical-stage licensing options to suppo...

April 02, 2026 | News

APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage

APAC Biopharma in Review: What Truly Moved the Needle This Year Asia-Pacific (APAC) has cemented its status as a pivotal biopharmaceutical hub in 2025, ma...

December 15, 2025 | Report

Takeda Steps Back from Cell & Gene Therapy to Refocus on Predictable Growth

Takeda Pharmaceutical, one of the world’s most globalised pharma companies, has confirmed it will step away from in-house development of its cell and...

October 05, 2025 | News

The $100 Billion Question: Can India Lead the Global Diabetes Economy?

India’s Diabetes Burden and Global Stakes: India is often called the “diabetes capital of the world,” and not without reason. Recent esti...

September 24, 2025 | Analysis | By editor@biopharmaapac.com

Could Early Lifestyle Interventions Change the Course of Type 2 Diabetes?

According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans have diabetes. Of these, around 90% to 95% have Type 2 diabete...

September 18, 2025 | News

The State of Biotech and Life Science Jobs in Asia Pacific – 2025

In 2025, Asia-Pacific has emerged as the fastest-growing hub for biotech and life sciences employment, fuelled by a powerful combination of government supp...

September 09, 2025 | Report

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus

The first seven months of 2025 saw robust dealmaking in China’s biopharma and healthcare sector, even as global headwinds tempered some activity. Chi...

August 15, 2025 | Report

“Spatial Biology at Scale: 10x Genomics CEO Serge Saxonov on Redefining Precision Medicine with TISHUMAP”

The future of medicine is being shaped at the intersection of spatial biology and artificial intelligence—and 10x Genomics is l...

August 07, 2025 | Interaction

Precision Medicine – Are We Ready for It?

Sarthak Ranade, Area Managing Director of Johnson & Johnson Innovative Medicine for SEA and India, believes the era of precision medicine is no longer ...

July 23, 2025 | Opinion | By Sarthak Ranade, Area Managing Director, J&J Innovative Medicine, SEA & India

BioPharma in APAC: Mid-Year Report 2025 – Tracking Progress, Trends & Possibilities Ahead

As we cross the midpoint of 2025, BioPharma APAC presents this Mid-Year Report—an incisive look at emerging biopharmaceutical dynamics, key i...

July 21, 2025 | Analysis

Unlocking Solubility as Lubrizol's Excipients Power the Next Generation of Drug Delivery

With up to 90% of new chemical entities suffering from poor water solubility, pharmaceutical innovators are under pressure to reformulate for eff...

July 09, 2025 | Interview

Smarter Together: How Molecule GEN Transforms Cross-Functional Drug Discovery

This cloud-native, SaaS-based platform breaks down traditional barriers in drug discovery by uniting all disciplines—biology, chemistry, and computat...

July 07, 2025 | Opinion | By Saurabh Singal | CEO-Founder, Molecule AI

Stay Connected